Paul Conyngham had no background in biology. He had a dying rescue dog, a data engineer's instincts, and a year he refused to waste. What followed was the first personalized mRNA cancer vaccine ever designed for a dog, built by someone who had never studied biology in his life. We broke down what his journey revealed about the information gap that slows every innovator down.
GLP‑1 receptor agonists have become the most discussed drug class in the world. They are celebrated for dramatic weight‑loss results, criticized for their influence on cultural beauty standards, blamed for repeated supply shortages of diabetes medications, and surrounded by almost constant industry speculation. This article draws on findings from Patsnap’s 2026 GLP1-R Market Landscape Report, which maps the full patent and clinical trial landscape shaping the next phase of the category.
AI can analyze millions of patents in seconds, but can it innovate? We break down what AI can and can't do for your R&D strategy and where the real opportunity lies.
As we move into 2026, innovation is accelerating at a pace few industries have experienced before. Advances in AI, growing geopolitical complexity, tighter R&D budgets, and rising competition are reshaping how ideas are created, protected, and commercialised. This article covers some of the key innovation, IP, and R&D trends to watch in 2026 and what they mean for those building, protecting, and scaling ideas.
2025 marked a decisive shift in how the world innovates. R&D investment reached new highs, competition intensified across nearly every technology domain, and the gap widened between companies that successfully integrated AI into their workflows and those that struggled to keep pace.
In the latest episode of Patsnap Spotlight, we meet Jerald Han, an NLP Engineer who offers a behind-the-scenes look at how our team designs and develops AI agents that power innovation for IP and R&D professionals worldwide.
In late 2025, a seemingly narrow advertising dispute told a much bigger story about the GLP-1 market. Novo Nordisk’s challenge to Regen Doctors’ promotional claims for compounded semaglutide led the telehealth clinic to voluntarily withdraw its superiority and safety claims.
Patsnap Analytics brings together 2+ billion global data points across 174 jurisdictions, giving IP and R&D teams a comprehensive view of patents, scientific literature, litigation, and market intelligence. Domain-specific AI cuts FTO and prior art search time from weeks to minutes, while 3D patent landscapes reveal competitive positioning and white space opportunities. Real-time monitoring and collaborative workspaces keep teams ahead of competitor activity and aligned across IP and R&D throughout the innovation lifecycle.
With AI now powering everything from target discovery to molecule design, the quality of data behind these models has become the new competitive differentiator. Yet for many teams, progress stalls due to one persistent problem: fragmented, biased, and unstructured public data that undermines the very models designed to accelerate discovery.
Engineering and R&D organizations are at a pivotal moment. A new global study by Capgemini shows an unmistakable trend: innovation is getting harder, more expensive, and more time-pressured. At the same time, AI is reshaping how new products, materials, drugs, and technologies are discovered.Leaders across industries agree on one thing: the next few years will determine who innovates and who falls behind.
Today, we’re excited to launch Patsnap Spotlight: The Minds Behind Our AI Agent, a new employee spotlight series that takes you behind the scenes to meet the engineers, scientists, and visionaries shaping the future of AI for R&D and IP.
Patsnap, the global leader in IP and R&D intelligence, and Uncountable, the modern platform for R&D data management, today announced a strategic partnership to launch a first-of-its-kind AI-powered Formulation Agent, marking a major leap forward in how R&D teams design, test and optimize complex formulations.
PatentBench is the first benchmark designed to test how AI performs on real patent tasks, beginning with one of the most rigorous: novelty search. Using expertly curated disclosures and gold-standard references, it brings clarity, structure, and measurable standards to a domain that has lacked all three for far too long.
It’s time to rethink how we tackle novelty assessments. Not with a one-size-fits-all approach, but with a system designed to handle complexity from every angle.
Patsnap is proud to share that our paper, “C.R.A.B: A Benchmark for Evaluating Curation of Retrieval-Augmented LLMs in Biomedicine,” has been accepted at EMNLP 2025, one of the world’s leading conferences in natural language processing.
Beyond the AI hype, Patsnap powers real innovation, combining deep domain intelligence and trusted data to help teams innovate with clarity and impact.
At Patsnap, protecting customer data is our top priority. We’re proud to share that we’ve achieved SOC 2 Type 1 certification, a key milestone that reinforces our commitment to the highest standards of security, availability, and integrity across all our platforms.
The MedTech landscape is evolving fast.AI diagnostics, wearable tech, and 3D-printed devices are transforming patient care but they’re also creating complex IP and regulatory hurdles.How do IP and R&D teams keep up?
Patsnap Singapore was honored to host senior business leaders from the UK, in collaboration with Plexal. The visit sparked rich conversations around innovation, leadership, and culture, bridging perspectives across borders.
We believe AI should amplify human intelligence, not replace it. It should empower you to think deeper, act smarter, and lead with confidence in every decision.
PatentBench is a benchmark designed to evaluate how AI performs on actual patent tasks, starting with one of the hardest: novelty search. Drawing from expertly curated disclosures and gold-standard references, it brings structure and clarity to a domain that has lacked both for far too long.
Policy teams inside the U.S. Commerce Department are weighing an annual fee tied to each patent’s market value. Early Treasury models point to tens of billions in new revenue, and The Wall Street Journal labels it a paradigm shift. Details remain fluid and Congress must still weigh in, but patent managers already share one question: How do we prepare if this becomes law?
In the fast-evolving world of biotech, artificial intelligence (AI) is reshaping how we discover and develop therapeutic antibodies. If AI can help us design new antibiotics to fight resistant bacteria, imagine what it can do for antibodies. Read on to find out how Chai-2 and Patsnap's Lao Tzu Dataset can help power up antibody drug discovery.
Manual novelty search is slow, inconsistent, and risky. Learn how AI agents streamline prior art analysis to boost grant rates and eliminate wasted effort.
Discover why diversity is critical to innovation success. Learn how diverse teams drive better outcomes, unlock new markets, and fuel inclusive innovation with data-backed insights.
Traditional patent search is no longer enough. Domain-specific AI is now essential for decoding complexity, surfacing trends early, and turning patent data into strategic advantage.